RNC Capital Management LLC Decreases Position in Eli Lilly and Company (NYSE:LLY)

RNC Capital Management LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 0.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 14,887 shares of the company’s stock after selling 103 shares during the period. RNC Capital Management LLC’s holdings in Eli Lilly and Company were worth $8,678,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Columbia Trust Co 01012016 grew its stake in shares of Eli Lilly and Company by 3.8% in the fourth quarter. Columbia Trust Co 01012016 now owns 1,056 shares of the company’s stock worth $616,000 after acquiring an additional 39 shares during the period. Cresta Advisors Ltd. bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $295,000. jvl associates llc grew its stake in shares of Eli Lilly and Company by 44.1% in the fourth quarter. jvl associates llc now owns 588 shares of the company’s stock worth $343,000 after acquiring an additional 180 shares during the period. Trust Co of the South bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $480,000. Finally, Sandy Cove Advisors LLC grew its stake in shares of Eli Lilly and Company by 0.8% in the fourth quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock worth $1,307,000 after acquiring an additional 17 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on LLY shares. Bank of America lifted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Barclays boosted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Truist Financial restated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $689.52.

Eli Lilly and Company Price Performance

LLY stock opened at $778.69 on Thursday. Eli Lilly and Company has a one year low of $334.58 and a one year high of $800.78. The company’s fifty day moving average price is $727.96 and its 200-day moving average price is $636.01. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The company has a market capitalization of $739.88 billion, a PE ratio of 134.26, a price-to-earnings-growth ratio of 1.70 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the previous year, the firm earned $2.09 earnings per share. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 195,055 shares of company stock valued at $125,254,657. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.